Table 2.
Comparison of the clinical features with published series in western countries
| Feature | Reference | |||||
|---|---|---|---|---|---|---|
| ILSG( 17 ) | Nathwani et al.( 5 ) | Berger et al.( 6 ) | Camacho et al.( 9 ) | Traverse‐Glehen et al.( 11 ) | Present series | |
| Number of cases | 20 | 20 | 37 | 24 | 21 | 65 |
| Male‐to‐female ratio | 1:1.4 | 1:1.3 | 1:1.3 | 1:2.1 | 2:1 | 1:1.3 |
| Median age (years) | 58 | 59 | 35% > 60 years | 62 | 57 | 64 |
| Performance status = 2 (%) | NA | 100 | 13 | NA | 81 | 6 |
| B symptoms (%) | NA | 14 | 14 | 20 | 10 | 8 |
| Extranodal involvement = 2 | NA | NA | 25 | NA | NA | 0 |
| Stage I/II (%) | 18 | 29 | 32 | 59 | 24 | 77 |
| Bone marrow infiltration (%) | 41 | 28 | 43 | 29 | 62 | 0 |
| LDH > normal values | NA | 36 | 40 | 42 | 48 | 12 |
| M‐protein | NA | NA | 8 | NA | 33 | 6 |
| International prognostic index 0/1 | 36 | 57 | 31 | 48 | NA | 71 |
| International prognostic index 4/5 | 9 | 7 | 5 | 5 | NA | 3 |
| 5‐year overall survival (%) | 57 | 56 | 55 | 79 | 70 | 85 |
| 5‐year failure‐free survival (%) | 29 | 28 | 29 | 22 | 35 | 65 |
LDH, lactate dehydrogenase; NA, not available.